Introduction
ARA-290 dosage for nerve repair and inflammation is an emerging topic in peptide and tissue-recovery research. ARA-290, also known as cibinetide, is a synthetic peptide derived from erythropoietin (EPO), designed to target tissue protection and anti-inflammatory pathways without stimulating red blood cell production.
Unlike traditional EPO, ARA-290 selectively activates the innate repair receptor (IRR), making it a promising compound in research focused on nerve regeneration, chronic inflammation, and cellular repair.
This comprehensive guide explores ARA-290 dosage, mechanism of action, benefits, usage frequency, cycle structure, and safety considerations from an educational and research-based perspective.
What is ARA-290?
ARA-290 is a small peptide engineered from the structure of erythropoietin, but modified to eliminate hematopoietic (red blood cell–stimulating) effects.
Key Characteristics:
- Non-erythropoietic
- Targets tissue repair pathways
- Focused on anti-inflammatory signaling
- Designed for neuroprotective research
It is widely studied in experimental settings related to:
- Nerve injury and neuropathy
- Chronic pain conditions
- Inflammatory disorders
How ARA-290 Works (Mechanism of Action)
ARA-290 binds to the innate repair receptor (IRR), a receptor involved in cellular healing and inflammation control.
Key Actions:
- Reduces inflammatory cytokine activity
- Promotes tissue repair signaling
- Supports nerve regeneration pathways
- Protects cells from damage
Unlike many peptides, ARA-290 does not affect hormone levels, making it unique in its category.
HGH 191AA Dosage Guide (Research-Based)
ARA-290 Dosage Guide
When discussing ARA-290 dosage for nerve repair and inflammation, usage is typically structured for daily administration in short cycles.
Standard Research Dosage
- Typical Range: 1 mg – 4 mg per day
- Administered via subcutaneous injection
Daily Usage Protocol
- Frequency: Once daily
- Some protocols use twice-daily dosing for enhanced exposure
Weekly Structure
- Daily injections (7 days/week)
- No off days in short-term protocols
Cycle Duration
- Short Research Cycle: 2–4 weeks
- Standard Cycle: 4–8 weeks
- Extended studies may vary depending on objectives
ARA-290 is generally used in shorter cycles compared to hormonal compounds.
Daily vs Weekly vs Monthly Use
Daily Use:
- Most effective for consistent receptor activation
Weekly Use:
- Not effective due to short half-life
Monthly Cycles:
- Used as structured short-term therapy blocks
ARA-290 in Nerve Repair Research
ARA-290 is primarily studied for its neuroprotective and regenerative properties.
Potential Research Benefits:
- Improved nerve regeneration
- Reduced neuropathic pain signals
- Enhanced sensory function recovery
- Protection against nerve damage
It has gained attention in studies involving small fiber neuropathy and nerve injury models.
ARA-290 for Inflammation Research
Chronic inflammation is a major target of ARA-290 research.
Observed Research Areas:
- Reduced inflammatory markers
- Improved tissue healing response
- Protection against oxidative stress
- Regulation of immune signaling
Its targeted action makes it distinct from broad-spectrum anti-inflammatory compounds.
Benefits of ARA-290
1. Anti-Inflammatory Action
Reduces cytokine-driven inflammation.
2. Nerve Regeneration Support
Promotes healing of damaged nerve tissue.
3. Tissue Protection
Helps prevent further cellular damage.
4. Non-Hormonal Mechanism
Does not interfere with endocrine balance.
5. Chronic Pain Research Potential
Studied for neuropathic pain modulation.
ARA-290 Cycle Structure
| Phase | Duration |
|---|---|
| Initiation | 1–2 weeks |
| Active | 2–4 weeks |
| Evaluation | 1–2 weeks |
Short, focused cycles are commonly used.
Possible Side Effects
ARA-290 is generally considered well-tolerated in research settings, but potential effects may include:
Potential Effects:
- Mild injection site irritation
- Temporary fatigue
- Headaches (rare)
- Dizziness (in some cases)
Risk Management
- Follow structured dosing protocols
- Avoid unnecessary prolonged use
- Monitor response markers
- Use sterile handling techniques
Stacking ARA-290 in Research Protocols
ARA-290 may be studied alongside other compounds for synergistic effects.
Common Research Pairings:
- Recovery peptides
- Anti-inflammatory agents
- Tissue repair compounds
The goal is to enhance healing and regeneration pathways.
Storage and Handling
- Store in a refrigerated environment (2–8°C)
- Protect from light exposure
- Use proper reconstitution practices
Peptides require careful storage to maintain stability.
For laboratory and research use only. This article summarizes published scientific literature for informational purposes. It is not intended for human or veterinary use, and nothing here is medical advice or a dosing recommendation.
Research References
- ARA 290, a nonerythropoietic peptide derived from EPO, attenuates neuropathic pain. PubMed
- Cibinetide (ARA 290) in sarcoidosis-associated small fiber neuropathy. PubMed
- Tissue-protective peptide ARA 290. PubMed
Written by Jay Cipollone, Founder & Research Lead, MyGLP1Store — a veteran-owned, U.S.-based research-peptide supplier with third-party lab testing and published certificates of analysis (COAs).